{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:01:02Z","timestamp":1787238062771,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.msard.2020.101935","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T19:45:13Z","timestamp":1578512713000},"page":"101935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["\u201cNo evidence of disease activity\u201d: Is it an aspirational therapeutic goal in multiple sclerosis?"],"prefix":"10.1016","volume":"40","author":[{"given":"El Najjar","family":"Mayssam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-6063","authenticated-orcid":false,"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-3242","authenticated-orcid":false,"given":"Salem","family":"Hannoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.101935_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12883-017-0799-0","article-title":"Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial","volume":"17","author":"Arnold","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418795085","article-title":"Peginterferon \u03b2-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis","volume":"11","author":"Arnold","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.101935_bib0003","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/1352458514546876","article-title":"Addressing the regulatory and scientific challenges in multiple sclerosis\u2013a statement from the EU regulators","volume":"20","author":"Balabanov","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00019052-200206000-00003","article-title":"The clinico-radiological paradox in multiple sclerosis revisited","volume":"15","author":"Barkhof","year":"2002","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0005","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.101935_bib0006","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2020.101935_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2016.12.001","article-title":"No evidence of disease activity (NEDA) in MS should include CSF biology \u2013 Towards a \u201cDisease-Free Status Score.\u201d","volume":"11","author":"Bonnan","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.101935_bib0008","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458510370464","article-title":"Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?","volume":"16","author":"Bosma","year":"2010","journal-title":"Mult. Scler"},{"key":"10.1016\/j.msard.2020.101935_bib0009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.msard.2020.101935_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1352458512444915","article-title":"Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab","volume":"19","author":"Button","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0012","first-page":"S69","article-title":"What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale","volume":"55","author":"\u00c7inar","year":"2018","journal-title":"Noro Psikiyatr. Ars."},{"key":"10.1016\/j.msard.2020.101935_bib0013","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.101935_bib0014","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.101935_bib0016","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awg081","article-title":"Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process","volume":"126","author":"Confavreux","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.101935_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neurad.2014.12.001","article-title":"OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol","volume":"42","author":"Cotton","year":"2015","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.msard.2020.101935_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12203","article-title":"Established and novel disease-modifying treatments in multiple sclerosis","author":"Cross","year":"2014","journal-title":"J. Intern. Med"},{"key":"10.1016\/j.msard.2020.101935_bib0019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458515604383","article-title":"No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy","volume":"22","author":"Damasceno","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.101935_bib0020","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","article-title":"Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes","volume":"74","author":"De Stefano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0021","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1212\/WNL.0000000000002105","article-title":"Long-term assessment of no evidence of disease activity in relapsing-remitting MS","volume":"85","author":"De Stefano","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0022","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nrneurol.2009.178","article-title":"Clinical prognostic factors in multiple sclerosis: a natural history review","volume":"5","author":"Degenhardt","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0023","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0024","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3174\/ajnr.A3107","article-title":"Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: Comparison of 7 quantification techniques","volume":"33","author":"Durand-Dubief","year":"2012","journal-title":"Am. J. Neurorad."},{"key":"10.1016\/j.msard.2020.101935_bib0025","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1212\/01.WNL.0000161871.83614.BB","article-title":"Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects","volume":"64","author":"Enzinger","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0026","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/WCO.0000000000000095","article-title":"Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?","volume":"27","author":"Filippi","year":"2014","journal-title":"Curr. Opin. Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0027","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1212\/01.WNL.0000036271.49066.06","article-title":"Eight-year follow-up study of brain atrophy in patients with MS","volume":"59","author":"Fisher","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0028","doi-asserted-by":"crossref","first-page":"e84162","DOI":"10.1371\/journal.pone.0084162","article-title":"Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model","volume":"8","author":"Fj\u00e6r","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2020.101935_bib0029","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge","volume":"92","author":"Gasperini","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2017.07.011","article-title":"A brief history of NEDA","volume":"20","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.101935_bib0031","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0b013e3182143345","article-title":"After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage","volume":"76","author":"Giovannoni","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0032","doi-asserted-by":"crossref","unstructured":"Giovannoni, G., Turner, B., Gnanapavan, S., Offiah, C., Schmierer, K., Marta, M., 2015. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? 4. 10.1016\/j.msard.2015.04.006.","DOI":"10.1016\/j.msard.2015.04.006"},{"key":"10.1016\/j.msard.2020.101935_bib0033","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1352458518773511","article-title":"Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b","volume":"25","author":"Goodin","year":"2019","journal-title":"Mult. Scler"},{"key":"10.1016\/j.msard.2020.101935_bib0034","first-page":"153","article-title":"Measurement of disability in multiple sclerosis","volume":"13","author":"Gray","year":"2008","journal-title":"Neurol. Asia"},{"key":"10.1016\/j.msard.2020.101935_bib0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fneur.2019.00788","article-title":"Prospective assessment of no evidence of disease activity-4 status in early disease stages of multiple sclerosis in routine clinical practice","volume":"10","author":"Guevara","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0036","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12974-018-1249-7","article-title":"Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis","volume":"15","author":"H\u00e5kansson","year":"2018","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2020.101935_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2018.03.017","article-title":"Diagnostic value of 3DFLAIR in clinical practice for the detection of infratentorial lesions in multiple sclerosis in regard to dual echo T2 sequences","volume":"102","author":"Hannoun","year":"2018","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.msard.2020.101935_bib0038","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12021-018-9408-7","article-title":"Automatic thalamus segmentation on unenhanced 3 d t1 weighted images: comparison of publicly available segmentation methods in a pediatric population","volume":"17","author":"Hannoun","year":"2019","journal-title":"Neuroinformatics"},{"key":"10.1016\/j.msard.2020.101935_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-317606","article-title":"Brain microstructural injury occurs in patients with RRMS despite \u201cno evidence of disease activity.\u201d","author":"Harel","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry JNNP"},{"key":"10.1016\/j.msard.2020.101935_bib0040","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Havrdov\u00e1","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.101935_bib0041","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0042","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/ene.13669","article-title":"\u2018No evidence of disease activity\u2019 \u2013 is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0043","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/135245859900500508","article-title":"Disease steps in multiple sclerosis: A longitudinal study comparing Disease Steps and EDSS to evaluate disease progression","volume":"5","author":"Hohol","year":"1999","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0044","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.neuroimage.2009.10.066","article-title":"Intra- and interscanner variability of automated voxel-based volumetry based on a 3 D probabilistic atlas of human cerebral structures","volume":"49","author":"Huppertz","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.msard.2020.101935_bib0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp-2013-306906","article-title":"Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study","volume":"85","author":"Jacobsen","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.101935_bib0046","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u201cno evidence of disease activity\u201d (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0047","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0048","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.60.3.339","article-title":"A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis","volume":"60","author":"Lai","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.101935_bib0049","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11940-018-0493-6","article-title":"Can Optical Coherence Tomography Be Used to Guide Treatment Decisions in Adult or Pediatric Multiple Sclerosis?","volume":"20","author":"Lambe","year":"2018","journal-title":"Curr. Treat. Options Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2017.12.016","article-title":"The evolution of &quot;No Evidence of Disease Activity&quot; in multiple sclerosis","volume":"20","author":"Lu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.101935_bib0051","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0052","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1191\/1352458505ms1182oa","article-title":"The association between cognitive impairment and physical disability in multiple sclerosis","volume":"11","author":"Lynch","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0053","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s13311-017-0561-8","article-title":"The role of advanced magnetic resonance imaging techniques in multiple sclerosis clinical trials","volume":"14","author":"Mahajan","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2020.101935_bib0054","article-title":"No evidence of disease activity including cognition (NEDA-3 plus) in na\u00efve pediatric multiple sclerosis patients treated with natalizumab","author":"Margoni","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0056","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.101935_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135974","article-title":"A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity","volume":"10","author":"Nygaard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2020.101935_bib0058","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/jnnp-2013-307275","article-title":"Isolated cognitive relapses in multiple sclerosis","volume":"85","author":"Pardini","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.101935_bib0059","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jns.2016.03.025","article-title":"Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis","volume":"364","author":"Prosperini","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.101935_bib0061","first-page":"85","article-title":"Minimal or no evidence of disease activity: which target to prevent long-term disability in multiple sclerosis?","volume":"23","author":"Prosperini","year":"2017","journal-title":"Mult. Scler. J"},{"key":"10.1016\/j.msard.2020.101935_bib0062","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1352458517698052","article-title":"Disability progression markers over 6-12\u2009years in interferon-\u03b2-treated multiple sclerosis patients","volume":"24","author":"R\u00edo","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0063","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0064","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1191\/1352458505ms1203oa","article-title":"Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients","volume":"11","author":"Rudick","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101935_bib0065","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archneurol.2010.150","article-title":"Disability progression in a clinical trial of relapsing-remitting multiple sclerosis eight-year follow-up","volume":"67","author":"Rudick","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0066","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.101935_bib0067","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.101935_bib0068","first-page":"455","article-title":"Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines","volume":"27","author":"Simon","year":"2006","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2020.101935_bib0069","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s13311-017-0548-5","article-title":"Therapeutic targets for multiple sclerosis: current treatment goals and future directions","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2020.101935_bib0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0071","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/1352458516644341","article-title":"Haematopoietic stem cell transplants should be a second-line therapy for highly active MS \u2013 NO","volume":"22","author":"Sorensen","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.101935_bib0072","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.101935_bib0073","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bpa.12641","article-title":"Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability","volume":"28","author":"Stankoff","year":"2018","journal-title":"Brain Pathol"},{"key":"10.1016\/j.msard.2020.101935_bib0074","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.101935_bib0075","doi-asserted-by":"crossref","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","author":"Traboulsee","year":"2016","journal-title":"Am. J. Neuroradiol"},{"key":"10.1016\/j.msard.2020.101935_bib0076","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ncl.2010.12.008","article-title":"Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?","volume":"29","author":"Trojano","year":"2011","journal-title":"Neurol. Clin"},{"key":"10.1016\/j.msard.2020.101935_bib0077","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1352458516650525","article-title":"Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?","volume":"23","author":"Uher","year":"2017","journal-title":"Mult. Scler"},{"key":"10.1016\/j.msard.2020.101935_bib0078","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflammat."},{"key":"10.1016\/j.msard.2020.101935_bib0079","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fneur.2019.00338","article-title":"Neurofilament light chain as a biomarker in multiple sclerosis","volume":"10","author":"Varhaug","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0080","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1007\/s00415-012-6762-5","article-title":"Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis","volume":"260","author":"Vrenken","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0081","first-page":"1045","article-title":"The natural history of multiple sclerosis: a geographically based study: 3","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Multivariate anal. Predict. Factors Models Outcome. Brain"},{"key":"10.1016\/j.msard.2020.101935_bib0082","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","article-title":"Assessing \u2018No evidence of disease activity\u2019 status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the multiple sclerosis clinical and magnetic resonance imaging outcom","volume":"32","author":"Weinstock-Guttman","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2020.101935_bib0083","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.101935_bib0084","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10072-018-3487-y","article-title":"Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity","volume":"39","author":"Yokote","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2020.101935_bib0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12883-016-0648-6","article-title":"Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod","volume":"16","author":"Ziemssen","year":"2016","journal-title":"BMC Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:38Z","timestamp":1761900578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":85,"alternative-id":["S2211034820300110"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.101935","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cNo evidence of disease activity\u201d: Is it an aspirational therapeutic goal in multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.101935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101935"}}